Operator of a non-profit healthcare system of hospitals, surgery centers, doctors, clinics and hospice providers intended to engage in medical practices. The company offers medical services that focus on cancer, heart, women, newborns, orthopedics, sports medicine, diagnostics, surgical and others, thereby enabling its patients to avail the service for care and treatment for a healthier living.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editingmore